Skip to main content
Clinical Trials/IRCT20231121060132N1
IRCT20231121060132N1
Recruiting
Phase 3

Investigating the effectiveness of famotidine as a radioprotector in reducing the mucosal and hematological complications of prostate cancer radiotherapy

Kermanshah University of Medical Sciences0 sites50 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Kermanshah University of Medical Sciences
Enrollment
50
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients aged 30 to 75 with prostate cancer candidates for radiotherapy
  • Do not receive PPI drugs and other H2 antagonist drugs

Exclusion Criteria

  • Lack of consent to participate in the study
  • Patients with kidney disease that cannot be prescribed famotidine

Outcomes

Primary Outcomes

Not specified

Similar Trials